Juva Life (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) is employing state-of-the-art science to discover, develop and commercialize safe and effective wellness and pharmaceutical products, in both the cannabis consumer segment as well as the non-cannabinoid based medical industry. The pharma R&D company just made a big discovery in their second novel drug compound, a proprietary non cannabinoid molecule that has been clinically observed to have potent anti-inflammatory effects.
Methodical, Efficient Approach to Drug Discovery Advances Non-Cannabinoid Molecule as Unique Development Candidate
Juva has in-house pharmaceutical research, development and consumer-facing operations in cannabis production and distribution, and they just announced the advancement of JUVA-041 into pre-clinical development, further substantiating their discovery strategy and technology platform.
Juva’s CEO & Founder Doug Chloupek commented, “While the clinical utility of cannabis has been ascribed to a small number of cannabinoid compounds, our platform has revealed that non-cannabinoid compounds possess potent anti-inflammatory properties seen in approved biologics.”
JUVA-019 and JUVA-041 Clinically Observed to Have Potent Anti-Inflammatory Properties
JUVA-041 is a small molecule isolated from cannabis uniquely identified by Juva Life. As with JUVA-019, JUVA-041 inhibits key cytokines proven to be of clinical relevance in inflammation but does so with differential selectivity and increased potency. Through the identification of JUVA-041 the company now has demonstrated the efficiency of its discovery approach, in uncovering a second small molecule from cannabis with bona fide anti-inflammatory properties. Juva believes that the observed clinical effects of cannabis are coupled to unappreciated small molecules with selective anti-inflammatory properties.
“JUVA-041 was identified through a chemocentric approach to bioactive identification,” said Sanjeev Gangwar, Ph.D., Vice President of Chemistry at Juva. “Our next steps will be to continue our discovery efforts to identify new leads and advance JUVA-019 and JUVA-041 through industry standard pre-clinical inflammatory models and non-clinical tests enabling IND filing.”
Chloupek added, “With the advancement of JUVA-041 as a lead candidate we have taken an additional step forward in demonstrating the robustness of our discovery strategy and technology platform.”
